中文
EN
News Center
News Center
Dr. Keene Wei of viwit Invited to Lecture at Provincial Capacity-Building Program for Drug and Cosmetics Inspectors
Author：
Release Time：
2026-09-30
Recently, the Provincial Capacity-Building Program for Drug and Cosmetics Inspectors, organized by the Shandong Center for Food and Drug Evaluation and Inspection, was successfully held in Jinan, Shandong Province.
Focusing on key areas including pharmaceutical manufacturing and cosmetics regulation, the program combined expert lectures, case studies, and hands-on field training to provide in-depth insights into emerging industry technologies and key compliance considerations. As an important initiative supporting the implementation of the province’s “Excellence Leadership” program and the development of a highly skilled evaluation and inspection workforce, the training was designed to further strengthen frontline inspectors’ professional expertise and regulatory capabilities and provide robust support for the continued professionalization of the province’s inspection team.
As a representative pharmaceutical technology company in Shandong Province, viwit was invited to participate in this high-level training program. Drawing on his extensive academic background and industry experience, Dr. Keene Wei, Chairman and President of viwit, delivered a presentation entitled “Current Development and Future Outlook of the Radiopharmaceutical Industry.” During the session, Dr. Wei provided inspectors from across the province with a systematic overview of emerging trends and technical challenges in the radiopharmaceutical field, with a particular focus on key considerations in targeted radiopharmaceuticals and theranostics.
During his presentation, Dr. Wei addressed some of the most recent developments shaping the industry. He began with the ongoing wave of mergers and acquisitions by multinational pharmaceutical companies in the radiopharmaceutical sector and went on to compare the current landscape of approved radiopharmaceuticals in China and international markets.
With a particular focus on inspectors’ practical regulatory responsibilities, Dr. Wei also reviewed the latest regulatory guidance from the U.S. Food and Drug Administration (FDA) and China’s Center for Drug Evaluation (CDE). He provided a detailed discussion of the critical role of radiation dosimetry in the safety evaluation and regulatory review of radiopharmaceuticals, as well as the key scientific and regulatory considerations involved.
In discussing current bottlenecks and future opportunities for the industry, Dr. Wei emphasized that transformative growth in the radiopharmaceutical sector will depend not only on breakthroughs in core technologies, but also on the coordinated advancement of regulatory review and oversight frameworks. Combining an in-depth analysis of technological evolution with practical considerations relevant to regulatory inspections, the presentation gave participating inspectors a clearer and more practical understanding of emerging review standards. The session concluded with an engaging discussion among attendees. 
Dr. Wei’s invitation to speak at the program reflects the recognition of his professional expertise by the provincial evaluation and inspection authority. It also represents a valuable opportunity to strengthen dialogue and collaboration between industry and regulatory authorities in support of continued progress across the pharmaceutical sector.
Building on this opportunity, viwit will continue to uphold its philosophy of “Innovation for a Better Life.” While advancing technological innovation, the company will remain firmly committed to rigorous quality standards and the fulfillment of its corporate social responsibilities. viwit will continue to contribute its expertise and capabilities to strengthening drug safety governance across Shandong Province and supporting the high-quality development of the pharmaceutical industry.